Home » Newsletters » BioWorld Science

BioWorld Science

April 21, 2005

View Archived Issues

Antitumor activity and toxicity of new lamellarin analogues

New business strategy at Questcor

Abiogen's cell therapy starts phase I/II trial in peritoneal carcinosis

Pivotal phase II study of Lomucin in CF gets Irish go-ahead

Preclinical evaluation of genetically engineered interferon omega

Clinical evidence supports the use of Fibrillex in patients with amyloid A amyloidosis

Pep:trans demonstrates ability to transport drug across blood-brain barrier

NIAID grant supports influenza vaccine development efforts at AlphaVax

Salvat to file Cetraxal Otic in U.S.

Roche files sNDA for Tamiflu

FDA 510(k) clearance for Cumulase

PDUFA action date extended for Entereg NDA

Ortho-McNeil to acquire Peninsula Pharmaceuticals

Enrollment closed in phase II Cloretazine study in AML, MDS

Pre-IND meeting for phase II study of arimoclomol in ALS

Novel MCH-R1 antagonist synthesized and tested

Novel prodrug of BDCRB with improved bioavailability

TargeGen describes synthesis and development of PI3K inhibitor TG-100-115

New Aurora kinase inhibitor PHA-680632 presented at AACR meeting

Safer administration schedule identified for anticancer V-ATPase inhibitor

Celera Genomics identifies novel HDAC inhibitor with promising antitumor activity

Canadian approval for Sativex

AZD-0530: a novel antiinvasive cancer therapy targeting Src and Abl kinases

A phase II study reports on the effects of ularitide in congestive heart failure

Update on the weight effects of AOD-9604 in obese patients

Phase II data on the antitumor effects of BMS-184476 in advanced NSCLC

Novel antibacterial agents disclosed in recent patent literature

Vertex, Achillion report novel anti-HCV drugs

GlaxoSmithKline claims new compounds for the treatment of anemia

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...